Genembryomics LTD F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
Australian genomics company GenEmbryomics Limited plans to raise capital through a U.S. IPO, offering 1,095,000 ordinary shares to fund operations and repay debt.
GenEmbryomics and Progenesis have signed a non-binding Memorandum of Understanding to collaborate on preimplantation genetic testing services, aiming to enhance market reach and service offerings.
GenEmbryomics Limited, an Australian genomics company, is seeking to raise capital through a U.S. initial public offering to further develop and commercialize its preimplantation genetic testing technology.